Roche confirms 2021 outlook as sales of diagnostics mitigate drop in COVID-19 drugs By Reuters

© Reuters. FILE PHOTO: Logo of Swiss pharmaceutical company Roche pictured in Rotkreuz

(Corrects the fall in sales in Swiss francs to 1%, not 3%, in the second paragraph)

ZURICH (Reuters) – Swiss drugmaker Roche said first quarter revenue increased 3% at constant currencies as sales of COVID-19 diagnostics helped offset lower activity main drug.

Sales amounted to 14.9 billion Swiss francs ($ 16.26 billion), which in Swiss francs was down 1% from 15.1 billion francs the previous year, Roche said. in a press release. The Basel-based company, which does not report quarterly profit, said the strength of the Swiss franc led to lower revenues.

The Basel-based company still expects current-year sales growth in the low to mid single-digit range at constant currencies, with similar basic earnings per share growth.

Warning: Fusion Media reminds you that the data contained in this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges but rather by market makers, so prices may not be precise and may differ from the actual market price. , which means that the prices are indicative and not suitable for negotiation purposes. Therefore, Fusion Media assumes no responsibility for any business losses that you may incur as a result of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any responsibility for loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Be fully informed of the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.